The global biologics contract manufacturing market is estimated to reach USD 19 billion in 2023 and is anticipated to grow at a CAGR of 9% during the forecast period 2023-2035.

The biologics contract manufacturing sector, synonymous with the biopharmaceutical CMO industry, exemplifies robust dynamism and rapid expansion, drawing considerable interest from various entities dedicated to research and development in pioneering new therapeutic modalities. These groundbreaking innovations encompass a spectrum of advancements, including antibody drug conjugates, biosimilars, and cell and gene therapies. Over time, this burgeoning market has seen a proliferation of more than 250 biologic therapies and vaccines worldwide. Notably, biologics demonstrate heightened success rates compared to traditional small-molecule drugs owing to their reduced off-target toxicity, a prevalent setback in small molecule drug development.

The escalating enthusiasm for biologics has triggered a discernible shift in investment trends within the pharmaceutical landscape, transitioning away from small molecule drugs and favoring biologics. This transition, combined with continuous scientific progress and the increasing number of FDA-approved biologics, signifies the advent of the biologics era. Biopharmaceuticals are expected to fundamentally redefine the pharmaceutical industry, gradually evolving into an indispensable component of mainstream medical treatments.

These service providers offer comprehensive solutions encompassing bioprocess development and optimization, aiming to expedite operational timelines and mitigate the substantial costs associated with manufacturing intricate biologic drugs. Some manufacturers choose to outsource specific operations to capitalize on state-of-the-art facilities and expertise, particularly when contract manufacturing firms employ cutting-edge technologies such as software-driven robotics to elevate manufacturing processes and minimize risks associated with manual methods. As outsourcing gains traction as a viable and advantageous business model within this sphere, the global market for biologics contract manufacturing is poised to witness remarkable growth in the forecast period.

Report Coverage
? The report delves into the biologics contract manufacturing market based on type of services offered, type of biologic manufactured, type of expression system used, scale of operation, company size and key geographical regions
? It analyzes factors such as drivers, restraints, opportunities, and challenges influencing market growth.
? Assessment of potential advantages and obstacles within the market, providing insights into the competitive landscape among top players.
? Revenue forecasts for market segments across five major regions.
? An executive summary detailing key research insights into the current state and anticipated evolution of the biologics contract manufacturing market in the short and long term.
? Introduction to biopharmaceuticals, manufacturing processes, expression systems, and the significance of outsourcing in this industry.
? Examination of the current market landscape of contract manufacturing companies, evaluating their services, biologic types, operational scale, expression systems, and geographical locations.
? Detailed profiles of key contract manufacturing organizations in each region, spotlighting their services, facilities, recent developments, and future prospects.
? Case studies on the biosimilars market, exploring opportunities for Contract Manufacturing Organizations (CMOs) and comparing small and large molecule drug characteristics and manufacturing processes.
? Assessment of big pharma manufacturing initiatives and collaborations, reviewing top companies’ initiatives, collaborations, trends, and activities impacting biologics contract manufacturing.
? Analysis of recent partnerships, mergers, acquisitions, and their influence on the biologics contract manufacturing industry.
? Review of expansion initiatives, funding investments, and technological advancements in biomanufacturing.
? Estimation of manufacturing capacity and annual demand for top biologics based on patient population, dosing, and strength.
? Evaluation of the total cost of ownership for CMOs based on company size from 2023-2043.
? Examination of industry trends, drivers, challenges through a SWOT analysis and their impact on the biopharmaceutical industry.
? Exploration of the role of the virtual business model in biopharmaceuticals, including its advantages, risks, and impact on outsourcing operations.
? Discussion of anticipated market growth, opportunities, and trends likely to shape the biologics contract manufacturing industry in the forecast period.

Key Market Companies
? AGC Biologics
? Boehringer Ingelheim
? Catalent
? Cell Therapies
? Charles River Laboratories
? FUJIFILM Diosynth Biotechnologies
? KBI Biopharma
? Kemwell Biopharma
? Lonza
? Miltenyi Biotec
? Minaris Regenerative Medicine
? Samsung Biologics
? Sandoz
? Vetter Pharma
? Wuxi Biologics